BD Announces Results for Second Fiscal Quarter

FRANKLIN LAKES, N.J., April 26 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) today reported record quarterly revenues of $1.449 billion for the second fiscal quarter ended March 31, 2006, representing an increase of 6 percent over the prior year period. This quarter's growth rate reflects an overall estimated 3 percent unfavorable impact from foreign currency translation, which affected all segments.

"We are very pleased with our strong second quarter results, which exceeded our expectations," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "We also closed the acquisition of GeneOhm, which will enable BD to further progress in the emerging field of healthcare- associated infections. The Company is well positioned to become a leader in the prevention and management of this global healthcare problem."

GeneOhm Sciences, Inc. Acquisition Completed

On February 14, 2006, BD announced the completion of its acquisition of GeneOhm Sciences, Inc. (GeneOhm), a company that has pioneered the development of molecular diagnostic testing for the rapid detection of bacteria, which cause healthcare-associated infections. Diluted earnings per share from continuing operations for the second quarter reflects a reduction of 1 cent per share related to the impact of GeneOhm operations for the second quarter. For the full fiscal year 2006, the Company expects diluted earnings per share from continuing operations to be reduced by approximately 7 cents related to the impact of GeneOhm operations. In addition, in the second quarter, the Company recorded an in-process research and development charge of $53 million associated with the acquisition, which further reduced diluted earnings per share from continuing operations by 21 cents in the quarter (see Table 1).

Analysis of Second Quarter and Six-month Period of Fiscal Year 2006 and 2005 Earnings

The following analysis of diluted earnings per share from continuing operations for the second quarter and six-month period of fiscal 2006 and 2005 identifies specified items that affect the comparability of results between periods.

(Table 1) Three Months Ended Six Months Ended March 31, March 31, % Incr./ FY2006 FY2005 (Decr.) FY2006 FY2005 % Incr. Diluted EPS from Continuing Operations:(1) $0.60 $0.71 -15% $1.45 $1.45 0% Specified Items: Insurance Settlements(2) (0.02) -- (0.04) -- In-Process Research and Development Charge(3) 0.21 0.21 Tax Examinations(4) -- -- -- (0.04) Tax Rate Impact(5) -- -- -- (0.02) Rounding -- -- -- (0.01) 0.19 -- 0.17 (0.07) Diluted EPS from Continuing Operations Excluding Specified Items:(1) $0.79 $0.71 11% $1.62 $1.38 17% (1) Includes the effect on diluted earnings per share from continuing operations of a 1 cent reduction in the second quarter and the six- month period ended March 31, 2006 relating to GeneOhm operations. (2) Represents the effect on diluted earnings per share from continuing operations of 2 cents in each of the first and second quarter of fiscal 2006 related to proceeds received from insurance settlements regarding the Company's previously owned latex glove business. (3) Represents the effect on diluted earnings per share from continuing operations of the in-process research and development charge recorded in the second quarter of fiscal 2006 related to the GeneOhm acquisition. (4) Represents the effect on diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter of 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions. (5) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005.

As illustrated in Table 1, diluted earnings per share from continuing operations, excluding specified items and including the dilutive impact on operating results from the acquisition, of 79 cents for the second fiscal quarter of 2006 increased by 11 percent over diluted earnings per share from continuing operations of 71 cents for the second fiscal quarter of 2005. For the six-month period, diluted earnings per share from continuing operations, excluding specified items and including the dilutive impact on operating results from the acquisition, of $1.62 for fiscal 2006 increased by 17 percent over diluted earnings per share from continuing operations, excluding specified items, of $1.38 for fiscal 2005.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $795 million, representing an increase of 9 percent from the prior year period. Strong sales in the Diabetes Care and Pharmaceutical Systems units contributed to the growth of the segment. U.S. sales of safety-engineered products totaled $123 million compared with $115 million in the prior year's quarter. The growth rate of safety-engineered products benefited, in part, from a favorable comparison to the prior year's revenues, which were negatively impacted by reductions in inventory by a major U.S. distributor. For the six- month period ended March 31, 2006, U.S. sales of safety-engineered products totaled $255 million compared with $241 million in the prior year's period. Included in BD Medical revenues were international sales of safety-engineered products of $22 million compared with $21 million in the prior year's quarter. For the six-month period ended March 31, 2006, international sales of safety- engineered products totaled $44 million compared with $39 million in the prior year's period. For the six-month period ended March 31, 2006, the BD Medical segment reported 10 percent revenue growth.

In the BD Diagnostics segment, worldwide revenues for the quarter were $434 million, representing an increase of 1 percent from the prior year period. The Preanalytical Systems unit of the segment reported revenue growth of 11 percent, benefiting from both BD Vacutainer(R) Push Button Blood Collection Set sales in the current year's quarter and a favorable comparison to the prior year's revenues, which were negatively impacted by reductions in inventory by a major U.S. distributor. U.S. sales of safety-engineered products totaled $97 million compared with $79 million in the prior year's quarter. For the six-month period ended March 31, 2006, U.S. sales of safety- engineered products totaled $193 million compared with $165 million in the prior year's period. Included in Preanalytical Systems revenues were international sales of safety-engineered products of $55 million compared with $47 million in the prior year's quarter. For the six-month period ended March 31, 2006, international sales of safety-engineered products totaled $107 million compared with $91 million in the prior year's period. Second quarter revenues in the Diagnostic Systems unit of the segment declined 8%, despite strong sales from diagnostic instrument platforms. For the most part, this decline in revenues was due to a relatively mild flu season in fiscal 2006 compared with 2005, in both Japan and the U.S. To a lesser extent, second quarter revenues were negatively impacted by the timing of early sales of flu diagnostic tests in the first fiscal quarter of 2006 and a challenging comparison to exceptionally strong sales of flu diagnostic tests in the prior year's quarter in Japan. For the six-month period ended March 31, 2006, the BD Diagnostics segment reported 4 percent revenue growth.

In the BD Biosciences segment, worldwide revenues from continuing operations for the quarter were $220 million, representing an increase of 8 percent from the prior year period. Flow cytometry instrument and reagent sales continued to be the primary growth contributors. Sales in the Discovery Labware unit as well as sales of cell imaging products also contributed to sales growth. For the six-month period ended March 31, 2006, the BD Biosciences segment reported 9 percent revenue growth, representing continued strong sales of flow cytometry instruments and reagents.

Geographic Results

Second quarter revenues in the U.S. were $702 million, representing an increase of 11 percent over the prior year period. Revenues outside the U.S. were $748 million, representing an increase of 2 percent over the prior year period, and reflected an estimated 5 percent unfavorable impact from foreign currency translation.

For the six-month period ended March 31, 2006, revenues in the U.S. were $1.383 billion, representing an increase of 10 percent over the prior year period. Revenues outside of the U.S. were $1.481 billion, representing an increase of 6 percent over the prior year period, and reflected an estimated 4 percent unfavorable impact from foreign currency translation.

Fiscal 2006 Outlook for Third and Fourth Quarters and Full Year

The following analysis of estimated diluted earnings per share from continuing operations for the third and fourth fiscal quarters and full fiscal year identifies specified items that affect the comparability of results between periods.

(Table 2) Three Months Three Months Ended Ended June 30, September 30, % % FY2006 FY2005 Incr. FY2006 FY2005 Incr. (Estimated) (Estimated) Diluted EPS from Continuing Operations:(1) $0.76-$0.78 $0.73 4-7% $0.80-$0.82 $0.47 70-74% Specified Items: Insurance Settlements(2) -- -- -- -- In-Process Research and Development Charge(3) -- -- -- -- Tax Examinations(4) -- -- -- -- Tax Rate Impact(5) -- 0.01 -- 0.02 Repatriation Tax Charge(6) -- -- -- 0.27 Rounding -- -- -- -- -- 0.01 -- 0.29 Diluted EPS from Continuing Operations Excluding Specified Items:(1) $0.76-$0.78 $0.74 3-5% $0.80-$0.82 $0.76 5-8% Twelve Months Ended September 30, FY2006 FY2005 % Incr. (Estimated) Diluted EPS from Continuing Operations:(1) $3.01-$3.05 $2.66 13-15% Specified Items: Insurance Settlements(2) (0.04) -- In-Process Research and Development Charge(3) 0.21 Tax Examinations(4) -- (0.04) Tax Rate Impact(5) -- -- Repatriation Tax Charge(6) -- 0.27 Rounding -- (0.01) 0.17 0.22 Diluted EPS from Continuing Operations Excluding Specified Items:(1) $3.18-$3.22 $2.88 10-12% (1) Includes the effect on estimated diluted earnings per share from continuing operations of a 3 cent reduction in each of the third and fourth quarters and a 7 cent reduction in the twelve-month period ended September 30, 2006 relating to GeneOhm operations. (2) Represents the effect on estimated diluted earnings per share from continuing operations of 2 cents in each of the first and second quarter of fiscal 2006 related to proceeds received from insurance settlements regarding the Company's previously owned latex glove business. (3) Represents the effect on estimated diluted earnings per share from continuing operations of the in-process research and development charge recorded in the second quarter of fiscal 2006 related to the GeneOhm acquisition. (4) Represents the effect on diluted earnings per share from continuing operations of the reversal of tax reserves in the first fiscal quarter of 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions. (5) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005. (6) Included in diluted earnings per share from continuing operations for the fourth quarter of fiscal 2005 is 27 cents per diluted share substantially related to the impact on taxes of the planned repatriation of $1.3 billion of foreign earnings under the provisions of the American Jobs Creation Act.

As illustrated in Table 2, the Company estimates that diluted earnings per share from continuing operations, including the expected dilutive impact on operating results from the acquisition, will increase approximately 3-5 percent for the third fiscal quarter of 2006 over diluted earnings per share from continuing operations, excluding specified items, of 74 cents for the third fiscal quarter of 2005. Excluding the expected dilutive impact of 3 cents on operating results from the acquisition, diluted earnings per share from continuing operations for the third fiscal quarter of 2006 are expected to be in the 79 to 81 cent range, representing an increase of 7-9 percent over diluted earnings per share from continuing operations, excluding specified items, of 74 cents for the third fiscal quarter of 2005.

The Company also estimates that diluted earnings per share from continuing operations, including the expected dilutive impact on operating results from the acquisition, will increase approximately 5-8 percent for the fourth fiscal quarter of 2006 over diluted earnings per share from continuing operations, excluding specified items, of 76 cents for the fiscal year 2005. Excluding the expected dilutive impact of 3 cents on operating results from the acquisition, diluted earnings per share from continuing operations for the fourth fiscal quarter of 2006 are expected to be in the 83 to 85 cent range, representing an increase of 9-12 percent over diluted earnings per share from continuing operations, excluding specified items, of 76 cents for the fourth fiscal quarter of 2005.

For the full fiscal year 2006, the Company estimates that diluted earnings per share from continuing operations, excluding specified items, and including the expected dilutive impact on operating results from the acquisition, are expected to be in the $3.18 to $3.22 range, representing an increase of approximately 10-12 percent over diluted earnings per share from continuing operations, excluding specified items, of $2.88 for the fiscal year 2005. Diluted earnings per share from continuing operations for the full year 2006, excluding specified items and the expected dilutive impact of 7 cents on operating results from the acquisition, are expected to be in the $3.25 to $3.29 range, representing an increase of 13-14 percent over diluted earnings per share from continuing operations, excluding specified items, of $2.88 for the fiscal year 2005.

Conference Call Information

A conference call regarding BD's second fiscal quarter results and its expectations for the third and fourth fiscal quarters will be broadcast live on BD's website, http://www.bd.com/investors, at 10:00 a.m. (ET) Wednesday, April 26, 2006. The conference call will be available for replay on BD's website, http://www.bd.com/investors, or at 1-800-272-5921 (domestic) and 1-402-220-9717 (international) through the close of business on Wednesday, May 3, 2006.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD, a leading global medical technology company that makes and sells medical devices, instrumented systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit http://www.bd.com/.

This press release, including the section entitled "Fiscal 2006 Outlook for Third and Fourth Quarters and Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; further increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY CONSOLIDATED INCOME STATEMENTS (Unaudited; Amounts in thousands, except per-share data) Three Months Ended March 31, 2006 2005 % Change REVENUES $1,449,317 $1,365,530 6.1 Cost of products sold 710,635 678,018 4.8 Selling and administrative 369,779 366,339 0.9 Research and development 129,099 (1) 65,988 95.6 TOTAL OPERATING COSTS AND EXPENSES 1,209,513 1,110,345 8.9 OPERATING INCOME 239,804 255,185 (6.0) Interest expense (19,805) (13,044) 51.8 Interest income 16,991 8,488 NM Other expense, net (451) (2,242) (79.9) INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 236,539 248,387 (4.8) Income tax provision 80,301 61,878 29.8 INCOME FROM CONTINUING OPERATIONS 156,238 186,509 (16.2) (LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF $(1,330) AND $1,015, RESPECTIVELY (2,170)(2) 1,641 NM NET INCOME $154,068 $188,150 (18.1) EARNINGS PER SHARE Basic: Income from continuing operations $0.63 $0.74 (14.9) (Loss) income from discontinued operations $(0.01) $0.01 NM Net income (3) $0.62 $0.74 (16.2) Diluted: Income from continuing operations $0.60 $0.71 (15.5) (Loss) income from discontinued operations $(0.01) $0.01 NM Net income (3) $0.60 $0.72 (16.7) AVERAGE SHARES OUTSTANDING Basic 248,088 253,427 Diluted 258,299 262,016 NM - Not Meaningful (1) Includes the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition. (2) Represents certain adjustments relating to the divestiture of Clontech. (3) Total per share amounts may not add due to rounding. BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION Three Months Ended March 31, (Unaudited; Amounts in thousands, except per-share data) 2006 As Insurance GeneOhm Excluding Reported Settlement(1) IPR&D(2) Items Selling and administrative 369,779 10,000 -- 379,779 as a % of revenues 25.5% 26.2% Research and development 129,099 -- (53,300) 75,799 as a % of revenues 8.9% 5.2% Operating Income 239,804 (10,000) 53,300 283,104 as a % of revenues 16.5% 19.5% Income taxes 80,301 (3,800) -- 76,501 effective tax rate 33.9% 27.3% Income from continuing operations 156,238 (6,200) 53,300 203,338 as a % of revenues 10.8% 14.0% Diluted earnings per share Income from continuing operations $0.60 $(0.02) $0.21 $0.79 (1) Represents the effect in the second fiscal quarter of 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business. (2) Represents the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition. BECTON DICKINSON AND COMPANY CONSOLIDATED INCOME STATEMENTS (Unaudited; Amounts in thousands, except per-share data) Six Months Ended March 31, 2006 2005 % Change REVENUES $2,863,378 $2,653,899 7.9 Cost of products sold 1,386,376 1,312,519 5.6 Selling and administrative 737,653 707,427 4.3 Research and development 198,424 (1) 128,071 54.9 TOTAL OPERATING COSTS AND EXPENSES 2,322,453 2,148,017 8.1 OPERATING INCOME 540,925 505,882 6.9 Interest expense (36,565) (27,371) 33.6 Interest income 31,662 13,693 NM Other expense, net (1,614) (5,103) (68.4) INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 534,408 487,101 9.7 Income tax provision 160,310 106,194 51.0 INCOME FROM CONTINUING OPERATIONS 374,098 380,907 (1.8) (LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF $(1,330) AND $1,638, RESPECTIVELY (2,170)(2) 2,594 NM NET INCOME $371,928 $383,501 (3.0) EARNINGS PER SHARE Basic: Income from continuing operations $1.51 $1.51 -- (Loss) income from discontinued operations $(0.01) $0.01 NM Net income $1.50 $1.52 (1.3) Diluted: Income from continuing operations $1.45 $1.45 -- (Loss) income from discontinued operations $(0.01) $0.01 NM Net income (3) $1.45 $1.46 (0.7) AVERAGE SHARES OUTSTANDING Basic 248,067 252,317 Diluted 257,145 262,393 NM - Not Meaningful (1) Includes the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition. (2) Represents certain adjustments relating to the divestiture of Clontech. (3) Total per share amounts may not add due to rounding. BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION (Unaudited; Amounts in thousands, except per-share data) 2006 As Insurance GeneOhm Excluding Reported Settlement(1) IPR&D(2) Items Selling and administrative 737,653 17,000 -- 754,653 as a % of revenues 25.8% 26.4% Research and development 198,424 -- (53,300) 145,124 as a % of revenues 6.9% 5.1% Operating Income 540,925 (17,000) 53,300 577,225 as a % of revenues 18.9% 20.2% Income taxes 160,310 (6,460) -- 153,850 effective tax rate 30.0% 27.0% Income from continuing operations 374,098 (10,540) 53,300 416,858 as a % of revenues 13.1% 14.6% Diluted earnings per share Income from continuing operations $1.45 $(0.04) $0.21 $1.62 (1) Represents the effect in 2006 related to proceeds received from insurance settlements in connection with the Company's previously owned latex glove business. (2) Represents the in-process research and development ("IPR&D") charge related to the GeneOhm acquisition. 2005 As Tax Tax Rate Excluding Reported Examinations(4) Impact(5) Charges Income taxes 106,194 11,265 6,240 123,699 effective tax rate 21.8% 25.4% Income from continuing operations 380,907 (11,265) (6,240) 363,402 as a % of revenues 14.4% 13.7% Diluted earnings per share Income from continuing operations (3) $1.45 $(0.04) $(0.02) $1.38 (3) Total per share amounts may not add due to rounding. (4) Relates to the reversal of tax reserves in the first fiscal quarter 2005 in connection with the conclusion of tax examinations in four non-U.S. jurisdictions. (5) Represents the effect on diluted earnings per share from continuing operations of tax-related events that caused the quarterly tax rate to vary from the then expected effective tax rate for fiscal year 2005. BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY SEGMENT AND GEOGRAPHIC AREA (Unaudited; Amounts in thousands) Three Months Ended March 31, 2006 2005 % Change BD MEDICAL United States $373,316 $330,044 13.1 International 422,022 401,621 5.1 TOTAL $795,338 $731,665 8.7 BD DIAGNOSTICS United States $232,913 $213,175 9.3 International 201,166 216,594 (7.1) TOTAL $434,079 $429,769 1.0 BD BIOSCIENCES United States $95,315 $86,947 9.6 International 124,585 117,149 6.3 TOTAL $219,900 $204,096 7.7 TOTAL REVENUES United States $701,544 $630,166 11.3 International 747,773 735,364 1.7 TOTAL $1,449,317 $1,365,530 6.1 BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY SEGMENT AND GEOGRAPHIC AREA (Unaudited; Amounts in thousands) Six Months Ended March 31, 2006 2005 % Change BD MEDICAL United States $739,899 $659,698 12.2 International 826,139 765,789 7.9 TOTAL $1,566,038 $1,425,487 9.9 BD DIAGNOSTICS United States $462,001 $431,883 7.0 International 415,932 411,669 1.0 TOTAL $877,933 $843,552 4.1 BD BIOSCIENCES United States $180,629 $162,644 11.1 International 238,778 222,216 7.5 TOTAL $419,407 $384,860 9.0 TOTAL REVENUES United States $1,382,529 $1,254,225 10.2 International 1,480,849 1,399,674 5.8 TOTAL $2,863,378 $2,653,899 7.9 BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS Three Months Ended March 31, (Unaudited; Amounts in thousands) United States 2006 2005 % Change BD MEDICAL Medical Surgical Systems $220,050 $203,671 8.0 Diabetes Care 115,726 94,482 22.5 Pharmaceutical Systems 32,028 26,772 19.6 Ophthalmic Systems 5,512 5,119 7.7 TOTAL $373,316 $330,044 13.1 BD DIAGNOSTICS Preanalytical Systems $125,412 $107,050 17.2 Diagnostic Systems 107,501 106,125 1.3 TOTAL $232,913 $213,175 9.3 BD BIOSCIENCES Discovery Labware $28,762 $26,689 7.8 Immunocytometry Systems 46,226 41,051 12.6 Pharmingen 20,327 19,207 5.8 TOTAL $95,315 $86,947 9.6 TOTAL UNITED STATES $701,544 $630,166 11.3 BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS Three Months Ended March 31, (continued) (Unaudited; Amounts in thousands) International % Change 2006 2005 Reported FX Neutral FX Impact BD MEDICAL Medical Surgical Systems $204,531 $198,621 3.0 4.7 (1.7) Diabetes Care 72,568 67,714 7.2 11.3 (4.1) Pharmaceutical Systems 135,081 125,999 7.2 16.6 (9.4) Ophthalmic Systems 9,842 9,287 6.0 13.4 (7.4) TOTAL $422,022 $401,621 5.1 9.8 (4.7) BD DIAGNOSTICS Preanalytical Systems $101,449 $97,785 3.7 8.2 (4.5) Diagnostic Systems 99,717 118,809 (16.1) (11.6) (4.5) TOTAL $201,166 $216,594 (7.1) (2.6) (4.5) BD BIOSCIENCES Discovery Labware $25,967 $25,722 1.0 7.2 (6.2) Immunocytometry Systems 77,348 72,709 6.4 12.1 (5.7) Pharmingen 21,270 18,718 13.6 20.9 (7.3) TOTAL $124,585 $117,149 6.3 12.4 (6.1) TOTAL INTERNATIONAL $747,773 $735,364 1.7 6.5 (4.8) BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS Three Months Ended March 31, (continued) (Unaudited; Amounts in thousands) Total % Change 2006 2005 Reported FX Neutral FX Impact BD MEDICAL Medical Surgical Systems $424,581 $402,292 5.5 6.4 (0.9) Diabetes Care 188,294 162,196 16.1 17.8 (1.7) Pharmaceutical Systems 167,109 152,771 9.4 17.2 (7.8) Ophthalmic Systems 15,354 14,406 6.6 11.4 (4.8) TOTAL $795,338 $731,665 8.7 11.3 (2.6) BD DIAGNOSTICS Preanalytical Systems $226,861 $204,835 10.8 12.9 (2.1) Diagnostic Systems 207,218 224,934 (7.9) (5.5) (2.4) TOTAL $434,079 $429,769 1.0 3.3 (2.3) BD BIOSCIENCES Discovery Labware $54,729 $52,411 4.4 7.5 (3.1) Immunocytometry Systems 123,574 113,760 8.6 12.3 (3.7) Pharmingen 41,597 37,925 9.7 13.3 (3.6) TOTAL $219,900 $204,096 7.7 11.2 (3.5) TOTAL REVENUES $1,449,317 $1,365,530 6.1 8.8 (2.7) BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS Six Months Ended March 31, (Unaudited; Amounts in thousands) United States 2006 2005 % Change BD MEDICAL Medical Surgical Systems $442,316 $419,177 5.5 Diabetes Care 226,127 182,943 23.6 Pharmaceutical Systems 60,428 46,821 29.1 Ophthalmic Systems 11,028 10,757 2.5 TOTAL $739,899 $659,698 12.2 BD DIAGNOSTICS Preanalytical Systems $248,201 $221,813 11.9 Diagnostic Systems 213,800 210,070 1.8 TOTAL $462,001 $431,883 7.0 BD BIOSCIENCES Discovery Labware $56,462 $50,783 11.2 Immunocytometry Systems 86,663 75,745 14.4 Pharmingen 37,504 36,116 3.8 TOTAL $180,629 $162,644 11.1 TOTAL UNITED STATES $1,382,529 $1,254,225 10.2 BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS Six Months Ended March 31, (continued) (Unaudited; Amounts in thousands) International % Change 2006 2005 Reported FX Neutral FX Impact BD MEDICAL Medical Surgical Systems $410,428 $392,679 4.5 5.0 (0.5) Diabetes Care 145,863 137,931 5.8 8.9 (3.1) Pharmaceutical Systems 250,444 216,635 15.6 23.8 (8.2) Ophthalmic Systems 19,404 18,544 4.6 10.6 (6.0) TOTAL $826,139 $765,789 7.9 11.2 (3.3) BD DIAGNOSTICS Preanalytical Systems $200,823 $191,543 4.8 7.9 (3.1) Diagnostic Systems 215,109 220,126 (2.3) 2.1 (4.4) TOTAL $415,932 $411,669 1.0 4.8 (3.8) BD BIOSCIENCES Discovery Labware $47,976 $48,591 (1.3) 3.8 (5.1) Immunocytometry Systems 149,763 138,115 8.4 13.3 (4.9) Pharmingen 41,039 35,510 15.6 21.5 (5.9) TOTAL $238,778 $222,216 7.5 12.5 (5.0) TOTAL INTERNATIONAL $1,480,849 $1,399,674 5.8 9.5 (3.7) BECTON DICKINSON AND COMPANY SUPPLEMENTAL REVENUE INFORMATION REVENUES BY BUSINESS SEGMENTS AND UNITS Six Months Ended March 31, (continued) (Unaudited; Amounts in thousands) Total % Change 2006 2005 Reported FX Neutral FX Impact BD MEDICAL Medical Surgical Systems $852,744 $811,856 5.0 5.3 (0.3) Diabetes Care 371,990 320,874 15.9 17.3 (1.4) Pharmaceutical Systems 310,872 263,456 18.0 24.7 (6.7) Ophthalmic Systems 30,432 29,301 3.9 7.6 (3.7) TOTAL $1,566,038 $1,425,487 9.9 11.6 (1.7) BD DIAGNOSTICS Preanalytical Systems $449,024 $413,356 8.6 10.0 (1.4) Diagnostic Systems 428,909 430,196 (0.3) 1.9 (2.2) TOTAL $877,933 $843,552 4.1 5.9 (1.8) BD BIOSCIENCES Discovery Labware $104,438 $99,374 5.1 7.6 (2.5) Immunocytometry Systems 236,426 213,860 10.6 13.7 (3.1) Pharmingen 78,543 71,626 9.7 12.6 (2.9) TOTAL $419,407 $384,860 9.0 11.9 (2.9) TOTAL REVENUES $2,863,378 $2,653,899 7.9 9.8 (1.9)